Biotech in 2025: A Retrospective

Why It Matters

The convergence of metabolic therapeutics, AI‑driven R&D, and radiopharma reshapes pipeline priorities and capital allocation, signaling new growth engines for the industry.

Key Takeaways

• GLP‑1 therapies dominate cardiometabolic market
• AI becomes standard R&D infrastructure across pharma
• Radiopharmaceuticals achieve core oncology strategy status
• Funding concentrates on late‑stage, high‑risk assets
• Precision psychiatry shows first biomarker‑guided success

Pulse Analysis

The metabolic health wave anchored 2025’s biotech narrative, with GLP‑1 agents moving beyond diabetes and weight loss into cardiovascular, renal, and even liver disease territories. Companies rushed to secure oral and next‑generation candidates, exemplified by Pfizer’s YaoPharma licensing and Roche’s partnership with Zealand Pharma. This crowded field is prompting insurers to rethink coverage as younger, healthier patients adopt these therapies, creating a new revenue horizon for both innovators and legacy pharma.

Artificial intelligence, once a buzzword, became a foundational tool across discovery, chemistry, and clinical operations. Physics‑informed models and generative‑design platforms now sit in production pipelines, enabling faster protein engineering and ligand scoring. Big players such as Eli Lilly and Novo Nordisk integrated AI at scale, while academic‑industry collaborations mined petabytes of cancer biobank data, halving preclinical timelines. The competitive edge now lies in how effectively firms blend AI with domain expertise rather than merely adopting the technology.

Radiopharmaceuticals completed their transition from niche oncology assets to core strategic bets, buoyed by Phase 3 wins like ITM‑11 and expanded indications for Novartis’ Pluvicto. The sector’s projected low‑double‑digit‑billion market by the early 2030s attracts M&A activity, yet also introduces supply‑chain and manufacturing complexities. Meanwhile, capital markets grew more discerning, channeling venture dollars toward de‑risked, late‑stage programs in cardiometabolic, AI‑enabled, and radiopharma spaces, leaving many mid‑cap innovators underfunded. This capital concentration underscores a broader industry shift: success now hinges on aligning breakthrough science with clear, asset‑centric commercial pathways.